Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleA physician's essay on grief and whale song points at something the medical record has never measured, that a family's wail carries real physiological information. Crying and whale calls have decades of published science behind them; the sound that fills an ICU when someone dies has no column in any chart.
Credit unions ranked among the best workplaces cap education benefits at $5,250, the largest amount the IRS lets an employer give tax-free. The figure was set in 1986 and never moved while tuition tripled and student debt topped $1.86 trillion, until an indexing fix finally arrives in 2027.
Turkish antitrust regulators are investigating Teva for patent-system manipulation and disparaging rivals, echoing a 2024 European Commission fine of 462.6 million euros for the same conduct around Copaxone. The accusation sits on the seam between the two companies Teva is: the generic challenger and the branded defender.
The standard playbook for a retiree with more than they'll spend, drain the tax-deferred account first, save the Roth, let the brokerage pass with its stepped-up basis, minimizes the heir's tax bill. It does so partly at the cost of the retiree's own flexibility, and the payoff depends on a future nobody has seen.
Federal Medicaid reductions are usually measured in coverage lost and dollars cut. In rural Maine, hospitals losing about 1 percent of revenue are dropping birthing units and leaning on a philanthropy-funded air ambulance service, turning a budget line into miles a family must drive at 2 a.m.
Massachusetts biopharma employment fell for the first time in two decades in 2025, even as the same industry snapshot shows 2026 venture funding up 25 percent and $18 billion in acquisitions. Jobs are the slowest signal in the industry; capital is the fastest, and the two numbers are just describing different years.
National cancer screening guidelines stop offering guidance for women past 75, exactly the age long-term care residents have often just entered. In the resulting silence, whether a resident gets screened is decided not by medicine but by who can arrange transportation to an off-site appointment.
A California hospital's drug-diversion AI flagged a nurse stealing patients' pain medication for weeks before anyone acted. The software did its job; the failure was in the unfunded human review every diversion system quietly depends on to turn a flag into an intervention.
Inflation is officially cooling to 3.4 percent, but consumer surveys show nearly 80 percent of households still cutting back and a third making extreme choices. The gap is not confusion, it is the difference between a flow the Fed can steer and a stock of accumulated prices that policy can never subtract from.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareGartner and Forrester categories for B2B, translated into plain-English analysis for buyers, not analyst-subscription holders.
Browse ResearchWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.